Nothing Special   »   [go: up one dir, main page]

WO2001013901A3 - A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress - Google Patents

A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress Download PDF

Info

Publication number
WO2001013901A3
WO2001013901A3 PCT/DK2000/000459 DK0000459W WO0113901A3 WO 2001013901 A3 WO2001013901 A3 WO 2001013901A3 DK 0000459 W DK0000459 W DK 0000459W WO 0113901 A3 WO0113901 A3 WO 0113901A3
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
delivery system
oxidative stress
pharmaceutical delivery
preventing
Prior art date
Application number
PCT/DK2000/000459
Other languages
French (fr)
Other versions
WO2001013901A2 (en
Inventor
Bent Hoejgaard
Henrik Enghusen Poulsen
Jukka Salonen
Original Assignee
Ferrosan As
Bent Hoejgaard
Henrik Enghusen Poulsen
Jukka Salonen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrosan As, Bent Hoejgaard, Henrik Enghusen Poulsen, Jukka Salonen filed Critical Ferrosan As
Priority to EP00952964A priority Critical patent/EP1210079A2/en
Priority to AU65589/00A priority patent/AU6558900A/en
Priority to PL00356667A priority patent/PL356667A1/en
Priority to JP2001518039A priority patent/JP2003507419A/en
Priority to NZ517833A priority patent/NZ517833A/en
Publication of WO2001013901A2 publication Critical patent/WO2001013901A2/en
Publication of WO2001013901A3 publication Critical patent/WO2001013901A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A pharmaceutical delivery system comprising a slow-release formulation of vitamin C (ascorbic acid) and a plain-release formulation of vitamin E (tocopherol) has been found to raise and maintain the concentrations of these vitamins in the blood plasma to a ratio of approximately 2.2:1. The steady-state concentration and ratio of these antioxidants has been found to be critical in the prevention and treatment of oxidative stress related disorders such as arteriosclerosis and diabetes and neural degenerative disorders such as Alzheimer's Disease.
PCT/DK2000/000459 1999-08-20 2000-08-18 A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress WO2001013901A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP00952964A EP1210079A2 (en) 1999-08-20 2000-08-18 A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress
AU65589/00A AU6558900A (en) 1999-08-20 2000-08-18 A pharmaceutical delivery system for vitamin c and vitamin and use of a combination of vitamin C and E for preventing or treating conditions involving oxidative stress
PL00356667A PL356667A1 (en) 1999-08-20 2000-08-18 A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress
JP2001518039A JP2003507419A (en) 1999-08-20 2000-08-18 Combination use of vitamin C and vitamin E for the prevention or treatment of symptoms including vitamin C and vitamin E drug delivery systems and oxidative stress
NZ517833A NZ517833A (en) 1999-08-20 2000-08-18 Oral delivery of antioxidants vitamin C and vitamin E combinations in slow- and plain-release formulations for treating oxidative stress

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199901145 1999-08-20
DKPA199901145 1999-08-20

Publications (2)

Publication Number Publication Date
WO2001013901A2 WO2001013901A2 (en) 2001-03-01
WO2001013901A3 true WO2001013901A3 (en) 2001-09-07

Family

ID=8101522

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2000/000459 WO2001013901A2 (en) 1999-08-20 2000-08-18 A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress

Country Status (8)

Country Link
EP (1) EP1210079A2 (en)
JP (1) JP2003507419A (en)
AR (1) AR025343A1 (en)
AU (1) AU6558900A (en)
NZ (1) NZ517833A (en)
PL (1) PL356667A1 (en)
RU (1) RU2309733C2 (en)
WO (1) WO2001013901A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
US9314527B2 (en) 2010-03-30 2016-04-19 Phosphagenics Limited Transdermal delivery patch
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078296A2 (en) * 1999-06-17 2000-12-28 Basf Aktiengesellschaft Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
CA2480227A1 (en) * 2002-03-28 2003-10-09 Oxis International, Inc. Neuroprotectant methods, compositions, and screening methods thereof
JP4690305B2 (en) * 2003-01-17 2011-06-01 バイタル ヘルス サイエンシズ プロプライアタリー リミティド Compounds with antiproliferative properties
EP1689381B1 (en) * 2003-09-05 2010-02-24 Matthias Rath Pharmaceutical composition comprising i.a. vitamin c, magnesium, green tea extract for retarding cardiovascular diseases (smc proliferation)
US10071030B2 (en) 2010-02-05 2018-09-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
ES2981002T3 (en) 2015-12-09 2024-10-04 Avecho Biotechnology Ltd Pharmaceutical formulation
EP3558903B1 (en) 2016-12-21 2024-07-03 Avecho Biotechnology Limited Process for phosphorylating a complex alcohol
JPWO2022059776A1 (en) * 2020-09-17 2022-03-24

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122157A (en) * 1977-03-04 1978-10-24 Richardson-Merrell Inc. Nitrofurantoin sustained release tablet
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
EP0176772A1 (en) * 1984-08-30 1986-04-09 RODISMA Pharmazeutische Produkte GmbH Process for sustaining the release of vitamins C and E
JPH07227256A (en) * 1993-12-24 1995-08-29 Takeda Chem Ind Ltd Liquid agent for oral administration
WO1997000672A1 (en) * 1995-06-23 1997-01-09 Defelice Stephen L Nutritional and/or dietary composition and method of using the same
EP0820703A1 (en) * 1996-07-22 1998-01-28 Valpharma S.A. Compositions for nutritional integration comprising prolonged-release hydrosoluble vitamins
US5897879A (en) * 1994-05-03 1999-04-27 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Sustained-release pharmaceutical system for the delivery of antioxidants
WO1999033448A1 (en) * 1997-12-23 1999-07-08 Merck Patent Gmbh Tablet for instant and prolonged release of one or more active substances
US6126969A (en) * 1996-02-27 2000-10-03 L. Perrigo Company Immediate release/sustained release compressed tablets

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122157A (en) * 1977-03-04 1978-10-24 Richardson-Merrell Inc. Nitrofurantoin sustained release tablet
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
EP0176772A1 (en) * 1984-08-30 1986-04-09 RODISMA Pharmazeutische Produkte GmbH Process for sustaining the release of vitamins C and E
JPH07227256A (en) * 1993-12-24 1995-08-29 Takeda Chem Ind Ltd Liquid agent for oral administration
US5897879A (en) * 1994-05-03 1999-04-27 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Sustained-release pharmaceutical system for the delivery of antioxidants
WO1997000672A1 (en) * 1995-06-23 1997-01-09 Defelice Stephen L Nutritional and/or dietary composition and method of using the same
US6126969A (en) * 1996-02-27 2000-10-03 L. Perrigo Company Immediate release/sustained release compressed tablets
EP0820703A1 (en) * 1996-07-22 1998-01-28 Valpharma S.A. Compositions for nutritional integration comprising prolonged-release hydrosoluble vitamins
WO1999033448A1 (en) * 1997-12-23 1999-07-08 Merck Patent Gmbh Tablet for instant and prolonged release of one or more active substances

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199543, Derwent World Patents Index; Class B05, AN 1995-331499, XP002901609 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
US9314527B2 (en) 2010-03-30 2016-04-19 Phosphagenics Limited Transdermal delivery patch
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound

Also Published As

Publication number Publication date
NZ517833A (en) 2004-01-30
AU6558900A (en) 2001-03-19
EP1210079A2 (en) 2002-06-05
AR025343A1 (en) 2002-11-20
PL356667A1 (en) 2004-06-28
RU2309733C2 (en) 2007-11-10
WO2001013901A2 (en) 2001-03-01
JP2003507419A (en) 2003-02-25
RU2002107015A (en) 2003-11-10

Similar Documents

Publication Publication Date Title
JP3156787B2 (en) Superoxide scavenger
US5843411A (en) Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use
KR100812596B1 (en) Compositions comprising compounds of natural origin for damaged skin
EP0903143A3 (en) Use of daidzein for the manufacture of a medicament for incraesing HDL cholesterol levels
WO2001095899A3 (en) Pharmaceutical compositions comprising cannabidiol derivatives
ATE205086T1 (en) USE OF THE CHELATING AGENT CLIOQUINOL FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF ALZHEIMER'S DISEASE
WO2001013901A3 (en) A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress
BRPI0111591B8 (en) compound, pharmaceutical composition, and uses of a compound
EP0766960A4 (en) External preparations for treating dermatoses
WO2001007064A1 (en) Synergistic antioxidant compositions in management of hemorrhoids and other ano-rectal inflammatory conditions
DE60004797D1 (en) MEDICINAL PRODUCTS WITH DELAYED DELIVERY OF ACTIVE SUBSTANCES CONTAINING ISOQUERCETINE AND ASCORBIC ACID
EP1351679B1 (en) Method and composition for the treatment of diabetic neuropathy
PL320687A1 (en) Use of incense for treating alzheimer disease
EP1393734A4 (en) Drugs for intestinal diseases
CN107158086A (en) With the skin care/therapeutic combination for alleviating itch effect
EP0910367B1 (en) Use of vitamin e acetate
JP2003506116A (en) Apparatus for spray dispensing a composition for topical application comprising vitamin E and essential fatty acids
EP1393738A4 (en) Drugs for diabetes
IT1314199B1 (en) COMPOSITIONS CONTAINING SUBSTANCES TO ADRENERGIC AND ESTRATTIVEGETALI FOR THE TREATMENT OF OVERWEIGHT AND OBESITY
WO2002005801A3 (en) Compositions containing diacyltartaric salts of (e)-metanicotine
WO2003002125A3 (en) Combination of aminosugars and cysteine or cysteine derivatives
ATE286402T1 (en) USE OF MORINDA CITRIFOLIA TO TREAT TINNITUS
EP1594456B1 (en) Use of a composition comprising vitamin k1 oxide or a derivative thereof for the treatment and/or the prevention of mammal dermatological lesions
HK1075654A1 (en) Hyperforin derivatives, the use thereof and formulations containing them
Thornfeldt Cosmeceuticals: separating fact from voodoo science

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000952964

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 517833

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 65589/00

Country of ref document: AU

ENP Entry into the national phase

Ref country code: RU

Ref document number: 2002 2002107015

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000952964

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 517833

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 517833

Country of ref document: NZ